Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.75 |
| ▸ | RAB9A | P51151 | 1/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15480561 | 0.88 | POLB (0.60) | NPC1RAB9AALDH1A1LMNAPOLB | |
| SCHEMBL1723104 | 0.85 | NPC1 (0.76) | NPC1RAB9AALDH1A1LMNAPOLB | |
| SCHEMBL15482013 | 0.78 | HDAC8 (0.71) | ALDH1A1POLBGAAHDAC3HDAC11 | |
| SCHEMBL15480623 | 0.77 | HPGD (0.57) | NPC1ALDH1A1LMNAPOLBGAA | |
| SCHEMBL9864972 | 0.76 | NPC1 (0.67) | NPC1RAB9AALDH1A1LMNAPOLB | |
| SCHEMBL15480539 | 0.76 | HDAC3 (0.74) | ALDH1A1LMNAPOLBGAAHDAC3 | |
| SCHEMBL15480530 | 0.76 | HDAC6 (0.74) | ALDH1A1LMNAHDAC3HDAC11HDAC8 | |
| SCHEMBL15480542 | 0.76 | HDAC3 (0.69) | ALDH1A1POLBHDAC3HDAC11HDAC8 | |
| SCHEMBL15480558 | 0.76 | HDAC8 (0.74) | ALDH1A1LMNAGAAHDAC3HDAC11 | |
| SCHEMBL15480538 | 0.76 | MEN1 (0.71) | ALDH1A1HDAC3HDAC11HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210060014-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB (SE) | 2021-03-04 | — | — | US | disclosed |
| US-20170020874-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENT AB (SE) | 2017-01-26 | — | — | US | disclosed |
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB | 2014-02-20 | — | — | US | disclosed |
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB | 2014-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | NPC1 2251/4885RAB9A 3597/4885ALDH1A1 3068/4885 |
| US-20170020874-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | NPC1 2251/4885RAB9A 3597/4885ALDH1A1 3068/4885 |
| US-20210060014-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | NPC1 2251/4885RAB9A 3597/4885ALDH1A1 3068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.